Extracellular vesicles: A new frontier in biomarker discovery for non-alcoholic fatty liver disease

International Journal of Molecular Sciences

Volumn 17, Issue 3, 2016, Pages

  Ban, Linda A ^a   Shackel, Nicholas A ^b   McLennan, Susan V ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CENTENARY INSTITUTE   (Australia)

Author keywords

Biomarkers; Diagnosis; Exosomes; Extracellular vesicles; Microvesicles; NAFLD; Non alcoholic steatohepatitis (NASH); Steatohepatitis; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ARGONAUTE 2 PROTEIN; ASIALOGLYCOPROTEIN RECEPTOR; BIOLOGICAL MARKER; CARBOXYLESTERASE; CD147 ANTIGEN; CD63 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; CHOLINE; CONNECTIVE TISSUE GROWTH FACTOR; ESCRT PROTEIN; GLYCOPROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TETRASPANIN; TRANSCRIPTOME;

APOPTOSIS; CELL ACTIVATION; CELL COMMUNICATION; CELL STRESS; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSESSMENT; DISEASE EXACERBATION; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME ACTIVITY; EPIGENETICS; EXOSOME; GLUCONEOGENESIS; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; INSULIN RESISTANCE; MULTIVESICULAR BODY; NATURAL KILLER T CELL; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PATHOLOGY; REVIEW; STEATOSIS; ANIMAL; BLOOD; NON-ALCOHOLIC FATTY LIVER DISEASE; SECRETION (PROCESS);

ANIMALS; BIOMARKERS; EARLY DIAGNOSIS; EXTRACELLULAR VESICLES; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84961884153     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17030376     Document Type: Review

References (93)

1. Hui, E.; Xu, A.; Bo Yang, H.; Lam, K.S. Obesity as the common soil of non-alcoholic fatty liver disease and diabetes: Role of adipokines. J. Diabetes Investig. 2013, 4, 413-425. [CrossRef] [PubMed]
2. Bugianesi, E.; Vanni, E.; Marchesini, G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr. Diabetes Rep. 2007, 7,175-180. [CrossRef]
3. Williams, K.H.; Shackel, N.A.; Gorrell, M.D.; McLennan, S.V.; Twigg, S.M. Diabetes and nonalcoholic fatty liver disease: A pathogenic duo. Endocr. Rev. 2013, 34, 84-129. [CrossRef] [PubMed]
4. Adams, L.A.; Harmsen, S.; St Sauver, J.L.; Charatcharoenwitthaya, P.; Enders, F.B.; Therneau, T.; Angulo, P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: A community-based cohort study. Am. J. Gastroenterol. 2010,105,1567-1573. [CrossRef] [PubMed]
5. Feng, R.N.; Du, S.S.; Wang, C.; Li, Y.C.; Liu, L.Y.; Guo, F.C.; Sun, C.H. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight chinese population. World J. Gastroenterol. 2014, 20, 17932-17940. [PubMed]
6. Kumar, R.; Rastogi, A.; Sharma, M.K.; Bhatia, V.; Garg, H.; Bihari, C.; Sarin, S.K. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J. Endocrinol. Metab. 2013,17,665-671. [CrossRef] [PubMed]
7. Younossi, Z.M.; Stepanova, M.; Negro, F.; Hallaji, S.; Younossi, Y.; Lam, B.; Srishord, M. Nonalcoholic fatty liver disease in lean individuals in the united states. Medicine 2012, 91, 319-327. [CrossRef] [PubMed]
8. LaBrecque, D.R.; Abbas, Z.; Anania, F.; Ferenci, P.; Khan, A.G.; Goh, K.L.; Hamid, S.S.; Isakov, V.; Lizarzabal, M.; Penaranda, M.M.; et al. World gastroenterology organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2014, 48, 467-473. [CrossRef] [PubMed]
9. Deffieux, T.; Gennisson, J.L.; Bousquet, L.; Corouge, M.; Cosconea, S.; Amroun, D.; Tripon, S.; Terris, B.; Mallet, V.; Sogni, P.; et al. Investigating liver stiffness and viscosity for fibrosis, steatosis and activity staging using shear wave elastography. J. Hepatol. 2015, 62, 317-324. [CrossRef] [PubMed]
10. Khov, N.; Sharma, A.; Riley, T.R. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J. Gastroenterol. 2014,20, 6821-6825. [CrossRef] [PubMed]
11. Myers, R.P.; Pomier-Layrargues, G.; Kirsch, R.; Pollett, A.; Beaton, M.; Levstik, M.; Duarte-Rojo, A.; Wong, D.; Crotty, P.; Elkashab, M. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe. J. Hepatol. 2012, 56, 564-570. [CrossRef] [PubMed]
12. Myers, R.P.; Pomier-Layrargues, G.; Kirsch, R.; Pollett, A.; Duarte-Rojo, A.; Wong, D.; Beaton, M.; Levstik, M.; Crotty, P.; Elkashab, M. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012, 55,199-208. [CrossRef] [PubMed]
13. Pais, R.; Charlotte, F.; Fedchuk, L.; Bedossa, P.; Lebray, P.; Poynard, T.; Ratziu, V.; Group, L.S. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol. 2013, 59, 550-556. [CrossRef] [PubMed]
14. Zelber-Sagi, S.; Yeshua, H.; Shlomai, A.; Blendis, L.; Leshno, M.; Levit, S.; Halpern, Z.; Oren, R. Sampling variability of transient elastography according to probe location. Eur. J. Gastroenterol. Hepatol. 2011, 23, 507-514. [CrossRef] [PubMed]
15. Athyros, V.G.; Katsiki, N.; Karagiannis, A.; Mikhailidis, D.P. Statins and nonalcoholic fatty liver disease: A bright future? Expert Opin. Investig. Drugs 2013,22,1089-1093. [CrossRef] [PubMed]
16. Angulo, P. Long-term mortality in nonalcoholic fatty liver disease: Is liver histology of any prognostic significance? Hepatology 2010, 51, 373-375. [CrossRef] [PubMed]
17. Arun, J.; Jhala, N.; Lazenby, A.J.; Clements, R.; Abrams, G.A. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes. Surg. 2007,17,155-161. [CrossRef] [PubMed]
18. Wolf, P. The nature and significance of platelet products in human plasma. Br. J. Haematol. 1967,13, 269-288. [CrossRef] [PubMed]
19. Dalton, A.J. Microvesicles and vesicles of multivesicular bodies versus "virus-like" particles. J. Natl. Cancer Inst. 1975, 54,1137-1148.
20. Bala, S.; Petrasek, J.; Mundkur, S.; Catalano, D.; Levin, I.; Ward, J.; Alao, H.; Kodys, K.; Szabo, G. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012, 56,1946-1957. [CrossRef] [PubMed]
21. Kornek, M.; Schuppan, D. Microparticles: Modulators and biomarkers of liver disease. J. Hepatol. 2012, 57, 1144-1146. [CrossRef] [PubMed]
22. Lemoinne, S.; Thabut, D.; Housset, C.; Moreau, R.; Valla, D.; Boulanger, C.M.; Rautou, P.E. The emerging roles of microvesicles in liver diseases. Nat. Rev. Gastroenterol. Hepatol. 2014, 11,350-361. [CrossRef] [PubMed]
23. Royo, F.; Falcon-Perez, J.M. Liver extracellular vesicles in health and disease. J. Extracell. Vesicles 2012,1. [CrossRef] [PubMed]
24. Ferrante, S.C.; Nadler, E.P.; Pillai, D.K.; Hubal, M.J.; Wang, Z.; Wang, J.M.; Gordish-Dressman, H.; Koeck, E.; Sevilla, S.; Wiles, A.A.; et al. Adipocyte-derived exosomal miRNAs: A novel mechanism for obesity-related disease. Pediatr. Res. 2015, 77, 447-454. [CrossRef] [PubMed]
25. Goichot, B.; Grunebaum, L.; Desprez, D.; Vinzio, S.; Meyer, L.; Schlienger, J.L.; Lessard, M.; Simon, C. Circulating procoagulant microparticles in obesity. Diabetes Metab. 2006, 32, 82-85. [CrossRef]
26. Nomura, S.; Inami, N.; Shouzu, A.; Urase, F.; Maeda, Y. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus. Platelets 2009, 20, 406-414. [CrossRef] [PubMed]
27. Wang, Y.; Chen, L.M.; Liu, M.L. Microvesicles and diabetic complications—Novel mediators, potential biomarkers and therapeutic targets. Acta Pharmacol. Sin. 2014, 35, 433-443. [CrossRef] [PubMed]
28. Akers, J.C.; Gonda, D.; Kim, R.; Carter, B.S.; Chen, C.C. Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J. Neuro-Oncol. 2013, 113, 1-11. [CrossRef] [PubMed]
29. Cocucci, E.; Meldolesi, J. Ectosomes and exosomes: Shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015, 25, 364-372. [CrossRef] [PubMed]
30. Kreimer, S.; Belov, A.M.; Ghiran, I.; Murthy, S.K.; Frank, D.A.; Ivanov, A.R. Mass-spectrometry-based molecular characterization of extracellular vesicles: Lipidomics and proteomics. J. Proteome Res. 2015,14, 2367-2384. [CrossRef] [PubMed]
31. Hurley, J.H.; Odorizzi, G. Get on the exosome bus with ALIX. Nat. Cell Biol. 2012,14, 654-655. [CrossRef] [PubMed]
32. Pols, M.S.; Klumperman, J. Trafficking and function of the tetraspanin CD63. Exp. Cell Res. 2009, 315, 1584-1592. [CrossRef] [PubMed]
33. Schutters, K.; Reutelingsperger, C. Phosphatidylserine targeting for diagnosis and treatment of human diseases. Apoptosis Int. J. Program. Cell Death 2010,15,1072-1082. [CrossRef] [PubMed]
34. Spronk, H.M.; ten Cate, H.; van der Meijden, P.E. Differential roles of tissue factor and phosphatidylserine in activation of coagulation. Thromb. Res. 2014,133, S54-S56. [CrossRef] [PubMed]
35. Albanyan, A.M.; Murphy, M.F.; Rasmussen, J.T.; Heegaard, C.W.; Harrison, P. Measurement of phosphatidylserine exposure during storage of platelet concentrates using the novel probe lactadherin: A comparison study with annexin V. Transfusion 2009, 49, 99-107. [CrossRef] [PubMed]
36. Connor, D.E.; Exner, T.; Ma, D.D.; Joseph, J.E. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb. Haemost. 2010,103,1044-1052. [CrossRef] [PubMed]
37. Dasgupta, S.K.; Guchhait, P.; Thiagarajan, P. Lactadherin binding and phosphatidylserine expression on cell surface-comparison with annexin A5. Transl. Res. J. Lab. Clin. Med. 2006,148,19-25. [CrossRef] [PubMed]
38. Quesenberry, P.J.; Goldberg, L.R.; Aliotta, J.M.; Dooner, M.S.; Pereira, M.G.; Wen, S.; Camussi, G. Cellular phenotype and extracellular vesicles: Basic and clinical considerations. Stem Cells Dev. 2014, 23,1429-1436. [CrossRef] [PubMed]
39. Xiong, W.; Sun, L.P.; Chen, X.M.; Li, H.Y.; Huang, S.A.; Jie, S.H. Comparison of microRNA expression profiles in HCC-derived microvesicles and the parental cells and evaluation of their roles in HCC. J. Huazhong Univ. Sci. Technol. Med. Sci. 2013, 33, 346-352. [CrossRef] [PubMed]
40. Witwer, K.W.; Buzas, E.I.; Bemis, L.T.; Bora, A.; Lasser, C.; Lotvall, J.; Nolte-'t Hoen, E.N.; Piper, M.G.; Sivaraman, S.; Skog, J.; et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles 2013, 2. [CrossRef] [PubMed]
41. Bergsmedh, A.; Szeles, A.; Henriksson, M.; Bratt, A.; Folkman, M.J.; Spetz, A.L.; Holmgren, L. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc. Natl. Acad. Sci. USA 2001, 98, 6407-6411. [CrossRef] [PubMed]
42. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495-516. [CrossRef] [PubMed]
43. Lynch, S.F.; Ludlam, C.A. Plasma microparticles and vascular disorders. Br. J. Haematol. 2007,137, 36-48. [CrossRef] [PubMed]
44. Ogasawara, F.; Fusegawa, H.; Haruki, Y.; Shiraishi, K.; Watanabe, N.; Matsuzaki, S. Platelet activation in patients with alcoholic liver disease. Tokai J. Exp. Clin. Med. 2005, 30, 41-48. [PubMed]
45. Stravitz, R.T.; Bowling, R.; Bradford, R.L.; Key, N.S.; Glover, S.; Thacker, L.R.; Gabriel, D.A. Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure. Hepatology 2013, 58, 304-313. [CrossRef] [PubMed]
46. Bernimoulin, M.; Waters, E.K.; Foy, M.; Steele, B.M.; Sullivan, M.; Falet, H.; Walsh, M.T.; Barteneva, N.; Geng, J.G.; Hartwig, J.H.; et al. Differential stimulation of monocytic cells results in distinct populations of microparticles. J. Thromb. Haemost. 2009, 7,1019-1028. [CrossRef] [PubMed]
47. Charrier, A.; Chen, R.; Chen, L.; Kemper, S.; Hattori, T.; Takigawa, M.; Brigstock, D.R. Exosomes mediate intercellular transfer of pro-fibrogenic connective tissue growth factor (CCN2) between hepatic stellate cells, the principal fibrotic cells in the liver. Surgery 2014,156, 548-555. [CrossRef] [PubMed]
48. Chen, L.; Charrier, A.; Zhou, Y.; Chen, R.; Yu, B.; Agarwal, K.; Tsukamoto, H.; Lee, L.J.; Paulaitis, M.E.; Brigstock, D.R. Epigenetic regulation of connective tissue growth factor by microRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. Hepatology 2014, 59,1118-1129. [CrossRef] [PubMed]
49. Kornek, M.; Popov, Y.; Libermann, T.A.; Afdhal, N.H.; Schuppan, D. Human t cell microparticles circulate in blood of hepatitis patients and induce fibrolytic activation of hepatic stellate cells. Hepatology 2011, 53, 230-242. [CrossRef] [PubMed]
50. Kogure, T.; Lin, W.L.; Yan, I.K.; Braconi, C.; Patel, T. Intercellular nanovesicle-mediated microRNA transfer: A mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 2011, 54, 1237-1248. [CrossRef] [PubMed]
51. Kogure, T.; Yan, I.K.; Lin, W.L.; Patel, T. Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: A mechanism of intercellular signaling in human hepatocellular cancer. Genes Cancer 2013, 4, 261-272. [CrossRef] [PubMed]
52. Fonsato, V.; Collino, F.; Herrera, M.B.; Cavallari, C.; Deregibus, M.C.; Cisterna, B.; Bruno, S.; Romagnoli, R.; Salizzoni, M.; Tetta, C.; et al. Human liver stem cell-derived microvesicles inhibit hepatoma growth in scid mice by delivering antitumor microRNAs. Stem Cells 2012, 30,1985-1998. [CrossRef] [PubMed]
53. Momen-Heravi, F.; Bala, S.; Kodys, K.; Szabo, G. Exosomes derived from alcohol-treated hepatocytes horizontally transfer liver specific miRNA-122 and sensitize monocytes to LPS. Sci. Rep. 2015, 5, 9991. [CrossRef] [PubMed]
54. Takahashi, K.; Yan, I.K.; Kogure, T.; Haga, H.; Patel, T. Extracellular vesicle-mediated transfer of long non-coding RNA ror modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio 2014, 4, 458-467. [CrossRef] [PubMed]
55. Lv, L.H.; Wan, Y.L.; Lin, Y.; Zhang, W.; Yang, M.; Li, G.L.; Lin, H.M.; Shang, C.Z.; Chen, Y.J.; Min, J. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J. Biol. Chem. 2012, 287,15874-15885. [CrossRef] [PubMed]
56. Xiao, W.; Dong, W.; Zhang, C.; Saren, G.; Geng, P.; Zhao, H.; Li, Q.; Zhu, J.; Li, G.; Zhang, S.; et al. Effects of the epigenetic drug MS-275 on the release and function of exosome-related immune molecules in hepatocellular carcinoma cells. Eur. J. Med. Res. 2013,18, 61. [CrossRef] [PubMed]
57. Zhang, J.; Shan, W.F.; Jin, T.T.; Wu, G.Q.; Xiong, X.X.; Jin, H.Y.; Zhu, S.M. Propofol exerts anti-hepatocellular carcinoma by microvesicle-mediated transfer of miR-142-3p from macrophage to cancer cells. J. Transl. Med. 2014,12, 279. [CrossRef] [PubMed]
58. Li, Y.; Zhang, L.; Liu, F.; Xiang, G.; Jiang, D.; Pu, X. Identification of endogenous controls for analyzing serum exosomal miRNA in patients with hepatitis B or hepatocellular carcinoma. Dis. Markers 2015, 2015, 893-894. [CrossRef] [PubMed]
59. Sugimachi, K.; Matsumura, T.; Hirata, H.; Uchi, R.; Ueda, M.; Ueo, H.; Shinden, Y.; Iguchi, T.; Eguchi, H.; Shirabe, K.; et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br. J. Cancer 2015,112, 532-538. [CrossRef] [PubMed]
60. Sun, L.; Hu, J.; Xiong, W.; Chen, X.; Li, H.; Jie, S. MicroRNA expression profiles of circulating microvesicles in hepatocellular carcinoma. Acta Gastro-Enterol. Belg. 2013, 76, 386-392.
61. Wang, H.; Hou, L.; Li, A.; Duan, Y.; Gao, H.; Song, X. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. BioMed Res. Int. 2014,2014, 864-894. [CrossRef] [PubMed]
62. Brodsky, S.V.; Facciuto, M.E.; Heydt, D.; Chen, J.; Islam, H.K.; Kajstura, M.; Ramaswamy, G.; Aguero-Rosenfeld, M. Dynamics of circulating microparticles in liver transplant patients. J. Gastrointest. Liver Dis. 2008,17, 261-268.
63. Freeman, C.M.; Quillin, R.C.; Wilson, G.C.; Nojima, H.; Johnson, B.L., 3rd; Sutton, J.M.; Schuster, R.M.; Blanchard, J.; Edwards, M.J.; Caldwell, C.C.; et al. Characterization of microparticles after hepatic ischemia-reperfusion injury. PLoS ONE 2014, 9, e97945. [CrossRef] [PubMed]
64. Costa-Silva, B.; Aiello, N.M.; Ocean, A.J.; Singh, S.; Zhang, H.; Thakur, B.K.; Becker, A.; Hoshino, A.; Mark, M.T.; Molina, H.; et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 2015,17, 816-826. [CrossRef] [PubMed]
65. Eldh, M.; Olofsson Bagge, R.; Lasser, C.; Svanvik, J.; Sjostrand, M.; Mattsson, J.; Lindner, P.; Choi, D.S.; Gho, Y.S.; Lotvall, J. MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma. BMC Cancer 2014,14, 962. [CrossRef] [PubMed]
66. Wang, X.; Ding, X.; Nan, L.; Wang, Y.; Wang, J.; Yan, Z.; Zhang, W.; Sun, J.; Zhu, W.; Ni, B.; et al. Investigation of the roles of exosomes in colorectal cancer liver metastasis. Oncol. Rep. 2015, 33, 2445-2453. [CrossRef] [PubMed]
67. Calabro, S.R.; Maczurek, A.E.; Morgan, A.J.; Tu, T.; Wen, V.W.; Yee, C.; Mridha, A.; Lee, M.; d'Avigdor, W.; Locarnini, S.A.; et al. Hepatocyte produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis. PLoS ONE 2014, 9, e90571. [CrossRef] [PubMed]
68. Lee, A.; Rode, A.; Nicoll, A.; Maczurek, A.E.; Lim, L.; Lim, S.; Angus, P.; Kronborg, I.; Arachchi, N.; Gorelik, A.; et al. Circulating CD147 predicts mortality in advanced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2016, 31, 459-466. [CrossRef] [PubMed]
69. Sidhu, S.S.; Mengistab, A.T.; Tauscher, A.N.; LaVail, J.; Basbaum, C. The microvesicle as a vehicle for emmprin in tumor-stromal interactions. Oncogene 2004, 23, 956-963. [CrossRef] [PubMed]
70. Millimaggi, D.; Mari, M.; D'Ascenzo, S.; Carosa, E.; Jannini, E.A.; Zucker, S.; Carta, G.; Pavan, A.; Dolo, V. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 2007, 9, 349-357. [CrossRef] [PubMed]
71. Zhang, W.; Zhao, P.; Xu, X.L.; Cai, L.; Song, Z.S.; Cao, D.Y.; Tao, K.S.; Zhou, W.P.; Chen, Z.N.; Dou, K.F. Annexin A2 promotes the migration and invasion of human hepatocellular carcinoma cells in vitro by regulating the shedding of CD147-harboring microvesicles from tumor cells. PLoS ONE 2013, 8, e67268. [CrossRef] [PubMed]
72. Kornek, M.; Lynch, M.; Mehta, S.H.; Lai, M.; Exley, M.; Afdhal, N.H.; Schuppan, D. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis c or nonalcoholic steatohepatitis. Gastroenterology 2012,143, 448-458. [CrossRef] [PubMed]
73. Baron, M.; Leroyer, A.S.; Majd, Z.; Lalloyer, F.; Vallez, E.; Bantubungi, K.; Chinetti-Gbaguidi, G.; Delerive, P.; Boulanger, C.M.; Staels, B.; et al. PPARa activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. Atherosclerosis 2011, 218, 69-76. [CrossRef] [PubMed]
74. Ajamieh, H.; Farrell, G.C.; McCuskey, R.S.; Yu, J.; Chu, E.; Wong, H.J.; Lam, W.; Teoh, N.C. Acute atorvastatin is hepatoprotective against ischaemia-reperfusion injury in mice by modulating enos and microparticle formation. Liver Int. 2015, 35, 2174-2186. [CrossRef] [PubMed]
75. Povero, D.; Eguchi, A.; Li, H.; Johnson, C.D.; Papouchado, B.G.; Wree, A.; Messer, K.; Feldstein, A.E. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS ONE 2014, 9, e113651. [CrossRef] [PubMed]
76. Povero, D.; Eguchi, A.; Niesman, I.R.; Andronikou, N.; de Mollerat du Jeu, X.; Mulya, A.; Berk, M.; Lazic, M.; Thapaliya, S.; Parola, M.; et al. Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require vanin-1 for uptake by endothelial cells. Sci. Signal. 2013, 6, ra88. [CrossRef] [PubMed]
77. Csak, T.; Bala, S.; Lippai, D.; Satishchandran, A.; Catalano, D.; Kodys, K.; Szabo, G. MicroRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 2015, 35,532-541. [CrossRef] [PubMed]
78. Kranendonk, M.E.; Visseren, F.L.; van Herwaarden, J.A.; Nolte-'t Hoen, E.N.; de Jager, W.; Wauben, M.H.; Kalkhoven, E. Effect of extracellular vesicles of human adipose tissue on insulin signaling in liver and muscle cells. Obesity 2014,22,2216-2223. [CrossRef] [PubMed]
79. Deng, Z.B.; Liu, Y.; Liu, C.; Xiang, X.; Wang, J.; Cheng, Z.; Shah, S.V.; Zhang, S.; Zhang, L.; Zhuang, X.; et al. Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. Hepatology 2009, 50, 1412-1420. [CrossRef] [PubMed]
80. Raubenheimer, P.J.; Nyirenda, M.J.; Walker, B.R. A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes 2006,55,2015-2020. [CrossRef] [PubMed]
81. Anstee, Q.M.; Goldin, R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006, 87,1-16. [CrossRef] [PubMed]
82. Murakami, Y.; Toyoda, H.; Tanahashi, T.; Tanaka, J.; Kumada, T.; Yoshioka, Y.; Kosaka, N.; Ochiya, T.; Taguchi, Y.H. Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS ONE 2012, 7, e48366.
83. Lagos-Quintana, M.; Rauhut, R.; Yalcin, A.; Meyer, J.; Lendeckel, W.; Tuschl, T. Identification of tissue-specific microRNAs from mouse. Curr. Biol. CB 2002,12, 735-739. [PubMed]
84. Barad, O.; Meiri, E.; Avniel, A.; Aharonov, R.; Barzilai, A.; Bentwich, I.; Einav, U.; Gilad, S.; Hurban, P.; Karov, Y.; et al. MicroRNA expression detected by oligonucleotide microarrays: System establishment and expression profiling in human tissues. Gen. Res. 2004,14, 2486-2494. [CrossRef] [PubMed]
85. Yamada, H.; Ohashi, K.; Suzuki, K.; Munetsuna, E.; Ando, Y.; Yamazaki, M.; Ishikawa, H.; Ichino, N.; Teradaira, R.; Hashimoto, S. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease. Clin. Chim. Acta Int. J. Clin. Chem. 2015, 446, 267-271. [CrossRef] [PubMed]
86. Koeck, E.S.; Iordanskaia, T.; Sevilla, S.; Ferrante, S.C.; Hubal, M.J.; Freishtat, R.J.; Nadler, E.P. Adipocyte exosomes induce transforming growth factor p pathway dysregulation in hepatocytes: A novel paradigm for obesity-related liver disease. J. Surg. Res. 2014,192,268-275. [CrossRef] [PubMed]
87. Itagaki, H.; Shimizu, K.; Morikawa, S.; Ogawa, K.; Ezaki, T. Morphological and functional characterization of non-alcoholic fatty liver disease induced by a methionine-choline-deficient diet in c57bl/6 mice. Int. J. Clin. Exp. Pathol. 2013, 6, 2683-2696. [PubMed]
88. Verma, S.; Jensen, D.; Hart, J.; Mohanty, S.R. Predictive value of alt levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013, 33,1398-1405. [CrossRef] [PubMed]
89. Fraser, R.; Cogger, V.C.; Dobbs, B.; Jamieson, H.; Warren, A.; Hilmer, S.N.; le Couteur, D.G. The liver sieve and atherosclerosis. Pathology 2012,44,181-186. [CrossRef] [PubMed]
90. Redzic, J.S.; Kendrick, A.A.; Bahmed, K.; Dahl, K.D.; Pearson, C.G.; Robinson, W.A.; Robinson, S.E.; Graner, M.W.; Eisenmesser, E.Z. Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-p1 and emmprin. PLoS ONE 2013, 8, e71225. [CrossRef] [PubMed]
91. He, M.; Qin, H.; Poon, T.C.; Sze, S.C.; Ding, X.; Co, N.N.; Ngai, S.M.; Chan, T.F.; Wong, N. Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and RNAs. Carcinogenesis 2015, 36,1008-1018. [CrossRef] [PubMed]
92. Farazuddin, M.; Dua, B.; Zia, Q.; Khan, A.A.; Joshi, B.; Owais, M. Chemotherapeutic potential of curcumin-bearing microcells against hepatocellular carcinoma in model animals. Int. J. Nanomed. 2014, 9, 1139-1152.
93. Laakso, T.; Edman, P.; Brunk, U. Biodegradable microspheres VII: Alterations in mouse liver morphology after intravenous administration of polyacryl starch microparticles with different biodegradability. J. Pharm. Sci. 1988, 77,138-144. [CrossRef] [PubMed]